Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 596

Results For "IT"

11090 News Found

Merck & Siemens join forces to accelerate AI drug discovery and development
Digitisation | September 24, 2025

Merck & Siemens join forces to accelerate AI drug discovery and development

Merck and Siemens signed new MoU extending their strategic partnership to accelerate digital transformation in the life science industry


Pharma Manufacturing & Automation Convention 2025 to be held on Oct. 8-9, 2025 in Hyderabad
News | September 24, 2025

Pharma Manufacturing & Automation Convention 2025 to be held on Oct. 8-9, 2025 in Hyderabad

Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices


FDA responds to evidence of possible association between autism and acetaminophen use during pregnancy
News | September 24, 2025

FDA responds to evidence of possible association between autism and acetaminophen use during pregnancy

Agency initiates safety label change and notifies physicians of possible link


Shelter Pharma installs 15 KW solar power plant
Sustainability | September 24, 2025

Shelter Pharma installs 15 KW solar power plant


Zydus, Pinkathon to drive awareness on breast cancer across India
Healthcare | September 24, 2025

Zydus, Pinkathon to drive awareness on breast cancer across India

Zydus Pinkathon will be led by women to raise awareness on breast cancer and women's health


Moderna delivers Canada’s first locally manufactured mRNA vaccines
News | September 23, 2025

Moderna delivers Canada’s first locally manufactured mRNA vaccines

All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec


Teva unveils promising SOLARIS resultsfor Olanzapine LAI
Clinical Trials | September 23, 2025

Teva unveils promising SOLARIS resultsfor Olanzapine LAI

No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks


Roche's Giredestrant combination meets phase III endpoints in advanced breast cancer
Clinical Trials | September 23, 2025

Roche's Giredestrant combination meets phase III endpoints in advanced breast cancer

Importantly, the combination of giredestrant and everolimus was well tolerated